IL-15 aggravates atherosclerotic lesion development in LDL receptor deficient mice

Vaccine. 2011 Jan 29;29(5):976-83. doi: 10.1016/j.vaccine.2010.11.037. Epub 2010 Nov 27.

Abstract

Background: Interleukin 15 (IL-15) is a pro-inflammatory cytokine involved in inflammatory diseases and IL-15 is expressed in atherosclerotic plaques.

Methods: To establish the role of IL-15 in atherosclerosis we studied the effect of IL-15 on atherosclerosis associated cells in vitro and in vivo by neutralizing IL-15 using a DNA vaccination strategy.

Results: Upon feeding a Western type diet LDLr(-/-) mice do express higher levels of IL-15 within the spleen and the number of IL-15 expressing cells among blood leukocytes and spleen cells is increased. Addition of IL-15 to macrophages induces the expression TNF-α and CCL-2. After the mice were vaccinated against IL-15, we observe a reduction in plaque size of 75% plaque. Unexpectedly, the relative number of macrophages within the plaque was 2-fold higher in IL-15 vaccinated mice than in control mice. Vaccination against IL-15 leads to an increased cytotoxicity against IL-15 overexpressing target cells, resulting in a reduction in IL-15 expressing cells and macrophages in blood and spleen and a decreased CD4/CD8 ratio.

Conclusion: Hypercholesterolemia leads to upregulation of IL-15 within spleen and blood. DNA vaccination against IL-15 does markedly reduces atherosclerotic lesion size, but does not promote lesion stability.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Atherosclerosis / immunology*
  • Atherosclerosis / pathology*
  • Chemokine CCL2 / biosynthesis
  • Interleukin-15 / antagonists & inhibitors
  • Interleukin-15 / immunology*
  • Interleukin-15 / toxicity*
  • Leukocytes / immunology
  • Male
  • Mice
  • Receptors, LDL / deficiency*
  • Spleen / immunology
  • Tumor Necrosis Factor-alpha / biosynthesis

Substances

  • Ccl2 protein, mouse
  • Chemokine CCL2
  • Interleukin-15
  • Receptors, LDL
  • Tumor Necrosis Factor-alpha